WHO ICTRP trial
A dose-exploratory Phase II clinical study to study the safety, efficacy, and…
ChiCTR2400081767 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR2400081767 |
|---|---|
| Public title | A dose-exploratory Phase II clinical study to study the safety, efficacy, and pharmacokinetic profile of PG-011 nasal spray in moderate-to-severe seasonal allergic rhinitis |
| Scientific title | A multicenter, randomized, double-blind, placebo-controlled dose-exploratory Phase II study to evaluate the safety, efficacy, and pharmacokinetic profile of PG-011 nasal spray in participants with moderate-to-severe seasonal allergic rhinitis |
| Primary sponsor | Beijing Tongren Hospital, Capital Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Allergic rhinitis |
| Interventions | Experimental group :PG-011 nasal spray;Control group:Placebo |
| Registration date | Mar 11, 2024 |
| Target size | Experimental group :120;Control group:40 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: